T1D, Metabolic Syndrome and Insulin Resistance

Completed

• Conditions: Type 1 Diabetes; Insulin Resistance; Metabolic Syndrome

• Registration Number: NCT05503303
• Lead Sponsor: Universidad Juárez Autónoma de Tabasco

Brief Summary

Patients with type 1 diabetes (T1D) and metabolic syndrome (MS) require high doses of insulin to achieve a glycemic control, due to insulin resistance (IR). The investigators identified the presence of metabolic syndrome and insulin resistance in patients with T1D in a population of southeast Mexico.

The sampled population was recruited from the Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez"; from August 2021 to February 2022, graduated physicians interviewed patients previously diagnosed with T1D. This study included patients older than 18 years and at least six months after being diagnosed with T1D. The interviewers excluded patients who did not attend regular consultations and those who did not agree to participate or to give a blood sample. A diabetologist evaluated and diagnosed all patients based on the World Health Organization (WHO) criteria.

Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols were determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics. The reasearch team determined glycated hemoglobin concentrations by an enzymatic immunoassay method.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-01
• Primary Completion: 2022-02-15
• Study Completion: 2022-03-01
• Status Verified: 2022-08
• Study First Submitted: 2022-08-13
• Study First Submitted QC: 2022-08-13
• Study First Posted: 2022-08-16
• Last Update Submitted: 2022-08-16
• Last Update Posted: 2022-08-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• At least six months after being diagnosed with T1D

Exclusion Criteria

• Did not attend regular consultations
• Did not agree to participate or to give a blood sample

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycated hemoglobin	March 2022	Concentrations by an enzymatic immunoassay method
Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols	March 2022	Determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics

Trial Locations

Locations (1)

Isela Esther Juarez Rojop; 🇲🇽 Villahermosa, Tabasco, Mexico